DBV Technologies (DBV) Q1 2026 earnings summary

Executive summary

• Focused on BLA filing for VIASKIN Peanut Patch for children 4-7 in H1 2026 and commercial launch readiness if approved.

• Preparing for BLA submission for toddlers 1-3 in H2 2026 and initiating Phase 2 THRIVE study in infants 6-12 months.

• Building on 2025 milestones: FDA regulatory alignment and positive Phase 3 results.

Financial highlights

• Cash and cash equivalents of $229 million as of March 31, 2026, up from $194 million at December 31, 2025.

• Net loss of $47.6 million for Q1 2026, compared to $27.1 million for Q1 2025.

• Net loss per share improved to $(0.11) from $(0.26) year-over-year due to strengthened equity base.

• Net cash used for operating activities was $49 million in Q1 2026, up from $20 million in Q1 2025.

• $89 million in net cash provided by financing activities in Q1 2026 after warrant exercises.

Outlook and guidance

• Cash runway expected to fund operations into Q2 2027, excluding additional programs or acquisitions.

• Commercial infrastructure build-out underway for potential U.S. launch of VIASKIN Peanut Patch.